Barcelona stands out as a vital hub for life sciences in Europe. Renowned for its architecture and vibrant culture, the city ranks sixth in scientific output and contributes significantly to Catalonia’s economy. In this article, we explore six biotech companies based in Barcelona that are pioneering therapies across various fields.
Accure Therapeutics: Pioneering Neuroprotection
Accure Therapeutics is making strides in the realm of neurodegenerative diseases. Their lead candidate, ACT-01, is a small molecule designed to activate trophic factor pathways, promoting cell survival and repairing damaged neurons. This therapy targets conditions such as optic neuritis and multiple sclerosis. Following positive preclinical safety results, ACT-01 is currently undergoing phase 2 trials, having met its primary safety endpoints.
In addition to ACT-01, Accure is developing ACT-02, aimed at treating Parkinson’s disease through the inhibition of prolyl oligopeptidase. This candidate has shown promise in improving cognition in preclinical models. Furthermore, ACT-03 is in the discovery phase, targeting epilepsy. With significant funding from The Michael J. Fox Foundation and government support, Accure is poised to advance its innovative therapies.
Oryzon Genomics: Modulating Gene Activity
Oryzon Genomics focuses on the epigenetic regulation of gene activity, particularly through histone-modifying enzymes. Their leading drugs, iadademstat and vafidemstat, are in clinical trials targeting cancers and central nervous system disorders. Iadademstat, a selective LSD1 inhibitor, is currently being evaluated in phase 1b and phase 2 trials for acute leukemia and small cell lung cancer.
Vafidemstat seeks to address neuroinflammation and cognitive impairment, showing promising results in animal models. As Oryzon continues to explore the potential of epigenetics, it aims to develop therapies that can effectively modulate disease pathways.
SpliceBio: Innovative Gene Therapy Approaches
SpliceBio, a spin-off from Princeton University, specializes in protein splicing technology. Their most advanced candidate, SB-007, targets Stargardt disease, a genetic eye disorder. By splitting the large ABCA4 gene into two parts and delivering them via separate adeno-associated virus (AAV) vectors, SpliceBio aims to restore the ABCA4 protein functionality within target cells.
Recently, SB-007 has gained fast track and orphan drug designations from the FDA, allowing for expedited development. With substantial funding secured in a series B round, SpliceBio is positioned to make significant advancements in gene therapy for rare diseases.
Peptomyc: Targeting Cancer at Its Core
Peptomyc is focused on inhibiting the MYC gene, a key driver in many cancers. The company’s candidate, OMO-103, is designed to directly target MYC and has already shown success in phase 2 trials for osteosarcoma. This innovative approach marks Peptomyc as a pioneer in targeting a gene that contributes to a vast array of malignancies.
Despite securing funding over two years ago, Peptomyc continues to gain traction, championing the development of direct MYC inhibitors to combat cancer effectively.
Ona Therapeutics: Advancing Antibody-Drug Conjugates
Ona Therapeutics is leading the charge in antibody-drug conjugate (ADC) therapy, combining monoclonal antibodies with cytotoxic agents to enhance cancer treatment precision. Their candidates, ONA-255 and ONA-389, target resistant breast cancer and colorectal cancer, respectively. With significant funding to advance their ADC pipeline, Ona Therapeutics is committed to developing targeted therapies for challenging cancer types.
Integra Therapeutics: Revolutionizing Gene Editing
Integra Therapeutics is at the forefront of gene editing technology, merging CRISPR-Cas with PiggyBac transposase to create precise gene insertion tools. Their Find and Cut-And-Transfer (FiCAT) technology is designed for both in vivo and ex vivo therapies, addressing high unmet medical needs in oncology and autoimmune disorders.
With recent investments bolstering their development efforts, Integra is well-positioned to make impactful contributions to the field of gene therapy.
Conclusion: A Thriving Biotech Ecosystem
Barcelona’s biotech landscape is rich with innovation and potential. The six companies highlighted are just a glimpse into the vibrant ecosystem fostering research and development in life sciences. With a strong focus on cancer therapies, gene editing, and neurodegenerative diseases, Barcelona is poised to remain a key player in the global biotech arena.
- Diverse Therapies: Companies are developing innovative treatments for a range of diseases, from neurodegenerative disorders to cancer.
- Strong Funding: Significant investments are fueling research and development across these biotech firms.
- Collaborative Environment: Barcelona’s research institutes and hospitals foster collaboration, driving advancements in life sciences.
- Focus on Gene Editing: Several companies are leveraging cutting-edge gene editing technologies to address unmet medical needs.
- Commitment to Innovation: The biotech sector in Barcelona is dedicated to pioneering new therapies and improving patient outcomes.
Read more → www.labiotech.eu